An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA).

By Mariam Sunny and Mrinalika Roy (Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Shares of Gilead Sciences Inc. (GILD) jumped more than 2% on Friday afternoon after the U.S. Supreme Court upheld a part of ...

The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

In observance of National HIV Testing Day Friday, several sites across South Florida are offering free rapid HIV testing and ...

The Supreme Court upheld free preventive care, rejecting a challenge that threatened coverage for STI testing, cancer ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.